Resource Library

Product Theater while attending The Liver Meeting® 2023
Hepatocellular Carcinoma (HCC) Surveillance Biomarker Landscape Overview

The full video highlights the clinical utility of FUJIFILM’s AFP-L3% and DCP serum biomarkers during HCC Surveillance. Dr. Yang discusses the patient populations most at-risk of developing HCC.

Contents:
– HCC Surveillance Improves Patient Outcome
– How to Use AFP-L3 and DCP as Risk Biomarkers?
– What is AFP-L3?
– What is DCP?
– Biomarker Elevations Before Diagnosis
– Combined Use of AFP-L3 and DCP
– How to Order AFP-L3 and DCP?

Contents:
– Intended Use
– Clinical Utility
– How to Order
– Laboratory Test Codes
– Reimbursement Codes

Contents:
– AFP-L3 and DCP HCC Risk Assessment
– Clinical Significance:
– How to Order
– Reimbursement Codes

Contents:
Proposed Algorithm for Surveillance of Hepatocellular Carcinoma
Published in Gastroenterology and Hepatology Volume 10, Issue 2 February 2014

Contents:
A regular surveillance program for patients at risk for development of Hepatocellular Carcinoma (HCC) is recommended by clinical practice guidelines worldwide.

Contents:

Contents:
– Intended Use
– Summary and explanation of the test
– Principle of the method
– Reagents
And more

Contents:
– Intended Use
– Summary and explanation of the test
– Principle of the method
– Reagents
And more